Replies to post #508614 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

I believe the patent should likely be issued soon, if all things go well. Yes, the patent puts NWBO into a prime position to negotiate with the various parties that have checkpoint inhibitor drugs and to generate revenues both as the provider of DCVax-L and also as a combination drug.

It will be interesting to see where this all takes them. That should be a very valuable patent potentially, though their primary value is still, IMHO, DCVax in its various platform options and in combination with many other possible oncology drugs and treatments.

Maybe even Novocure will want to do combination trials. You never know who might show up at their door looking for major validation in combination with DCVax-L.

[flipper44]

Nwbo owns the potential double combo ip. A patent has not been granted yet, but one of the two applications should get there soon. My guess is that anything added to any double patent combo (for example csf1r inhibitor**), would also be protected for the term of any prior double combo patent.

**That is the holy (trinity) grail combo, and the next spore trial.